Binding Molecules Specific for CD73 and Uses Thereof
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 5 of these applications claim priority to application 62/077,486, filed Nov 10, 2014. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,938,356 | Binding Molecules Specific for CD73 and Uses Thereof In force · High confidence | MedImmune Limited | In force | High confidence | ||
| US 10,287,362 | Binding Molecules Specific for CD73 and Uses Thereof In force · High confidence | MedImmune Limited | In force | High confidence | ||
| US 10,556,968 | Binding Molecules Specific for CD73 and Uses Thereof In force · High confidence | MedImmune Limited | In force | High confidence | ||
| US 11,525,012 | Binding Molecules Specific for CD73 and Uses Thereof In force · High confidence | MedImmune Limited | In force | High confidence | ||
| US 12,630,648 | Binding Molecules Specific for CD73 and Uses Thereof In force · High confidence | MedImmune Limited | In force | High confidence | ||
| Application 18/246,206 | Treatment Methods Using ANTI-CD73 and ANTI-PD-L1 Antibodies and Chemotherapy Abandoned Abandoned Jun 20, 2026 | MedImmune, LLC | Abandoned | Abandoned Jun 20, 2026 | ||
| Application 19/668,065 | Binding Molecules Specific for CD73 and Uses Thereof Pending Not granted | MedImmune Limited | Pending | Not granted |
7 of 7 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
5 of these are in force and held by MedImmune, LLC.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.